Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
No Settlements as Federal Opioid Cases Move to Trial
Judge Dan Aaron Polster of the Northern District of Ohio will preside over three consolidated federal lawsuits against makers and distributors of opioids in...
PhRMA Calls Out Foreign Countries Over Patent and Pricing Policies
PhRMA, the pharmaceutical industry’s trade group, filed comments with the Office of the U.S. Trade Representative asking for “urgent action” against two dozen countries...
Is Alexa the Newest Member of the Health-Care Team?
Hospitals are exploring new ways to incorporate voice-activated technologies like Amazon’s Alexa and Google Assistant into patient visits, suggesting a future in which these...
Roche Will Donate Hemophilia A Drug to Developing Countries
Roche will donate its new hemophilia A drug emicizumab-kxwh to the World Hemophilia Federation (WHF) Humanitarian Aid Program. Roche joins other companies – including...
Democrats to Begin Medicare Expansion Hearings
Democrats will begin holding hearings on expanding Medicare this spring and are aiming to pass a bill in time for the next presidential term....
Current Issue
February 2019, Volume 5, Issue 3
This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.
